2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…2016 American Transplant Congress
HLA Antibody in Transplant Recipients During Transition from Paediatrics.
Objective:Adolescent transplant recipients in transition from paediatric to adult units are known to be at high risk of graft failure. Detection of HLA antibody is…2016 American Transplant Congress
Mining the Human Proteome for Monitoring Renal Transplant Injury.
The human urinary proteome reflects systemic and inherent renal injury perturbations and can be harnessed to define biomarkers for different kidney transplant injury states. Through…2016 American Transplant Congress
Accumulation of Highly Sensitized Patients in a KPD Registry.
University of Toledo, Toledo, OH.
Objectives: We analyzed sensitization against HLA among patients in a kidney paired donation (KPD) registry. In particular, three groups of patients were included: 1) all…2016 American Transplant Congress
Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results.
Previous studies demonstrated the significance of angiotensin II type-1 receptor antibodies (AT1Rabs) in processes including hypertension, cardiac hypertrophy and renal fibrosis; information regarding ventricular and…2016 American Transplant Congress
End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy.
Background Alloantigen-specific natural occurring regulatory T cells (nTregs) have the potential to offer a more targeted approach of immunosuppression and are the cell type of…2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…2016 American Transplant Congress
Biopsies for Delayed Graft Function After Alemtuzumab Induction in Kidney Transplantation: The Incidence of Early Rejection After Alemtuzumab Is Very Low but Not Negligible.
IntroductionUK practice advocates transplant biopsy (Bx) at day 7, then weekly in the presence of delayed graft function (DGF) because if missed, early rejection adversely…2016 American Transplant Congress
Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients.
MicroRNAs (miRs) have been reported to play a role in immune system response. The results of several clinical trials have suggested that these molecules might…
- « Previous Page
- 1
- …
- 402
- 403
- 404
- 405
- 406
- …
- 531
- Next Page »